reviewThe AAPS JournalMar 9, 2012HYBRID OA

Challenges in Development of Nanoparticle-Based Therapeutics

Abraxis (United States) · Bristol-Myers Squibb (Switzerland)

PubMed
Indexed incrossrefpubmed

Abstract

In recent years, nanotechnology has been increasingly applied to the area of drug development. Nanoparticle-based therapeutics can confer the ability to overcome biological barriers, effectively deliver hydrophobic drugs and biologics, and preferentially target sites of disease. However, despite these potential advantages, only a relatively small number of nanoparticle-based medicines have been approved for clinical use, with numerous challenges and hurdles at different stages of development. The complexity of nanoparticles as multi-component three dimensional constructs requires careful design and engineering, detailed orthogonal analysis methods, and reproducible scale-up and manufacturing process to achieve…

Citation impact

1,088
total citations
FWCI
20.78
Percentile
100%
References
89
Citations per year

Authors

1

Topics & keywords

Keywords
  • Context (archaeology)
  • Risk analysis (engineering)
  • Nanotechnology
  • Process (computing)
  • New product development
  • Drug development
  • Nanomedicine
  • Computer science
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding